Chimeric Therapeutics (ASX:CHM) Accounts Payable & Accrued Expense : A$6.72 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Chimeric Therapeutics Accounts Payable & Accrued Expense?

Chimeric Therapeutics's quarterly accounts payable & accrued expense increased from Dec. 2022 (A$3.41 Mil) to Jun. 2023 (A$10.81 Mil) but then declined from Jun. 2023 (A$10.81 Mil) to Dec. 2023 (A$6.72 Mil).

Chimeric Therapeutics's annual accounts payable & accrued expense increased from Jun. 2021 (A$3.03 Mil) to Jun. 2022 (A$6.37 Mil) and increased from Jun. 2022 (A$6.37 Mil) to Jun. 2023 (A$10.81 Mil).

Chimeric Therapeutics Accounts Payable & Accrued Expense Historical Data

The historical data trend for Chimeric Therapeutics's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chimeric Therapeutics Accounts Payable & Accrued Expense Chart

Chimeric Therapeutics Annual Data

Trend

Jun21

Jun22

Jun23

Accounts Payable & Accrued Expense

3.03

6.37

10.81

Chimeric Therapeutics Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial			4.33	6.37	3.41	10.81	6.72

Chimeric Therapeutics Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Chimeric Therapeutics (ASX:CHM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimeric Therapeutics Ltd (ASX:CHM) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

CHMMF:USA

Address

62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053

Website

https://www.chimerictherapeutics.com

Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.

Chimeric Therapeutics (ASX:CHM) Headlines

No Headlines